WallStSmart

Kimberly-Clark Corporation (KMB)vs22nd Century Group Inc (XXII)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Kimberly-Clark Corporation generates 234770% more annual revenue ($16.56B vs $7.05M). KMB leads profitability with a 12.8% profit margin vs -71.7%. KMB earns a higher WallStSmart Score of 63/100 (C+).

KMB

Buy

63

out of 100

Grade: C+

Growth: 4.7Profit: 8.0Value: 4.0Quality: 4.0
Piotroski: 3/9Altman Z: 2.19

XXII

Avoid

31

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

KMBSignificantly Overvalued (-19.0%)

Margin of Safety

-19.0%

Fair Value

$90.45

Current Price

$98.43

$7.98 premium

UndervaluedFair: $90.45Overvalued
XXIIUndervalued (+70.6%)

Margin of Safety

+70.6%

Fair Value

$19.09

Current Price

$1.56

$17.53 discount

UndervaluedFair: $19.09Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

KMB1 strengths · Avg: 10.0/10
Return on EquityProfitability
111.7%10/10

Every $100 of equity generates 112 in profit

XXII1 strengths · Avg: 10.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Areas to Watch

KMB4 concerns · Avg: 3.3/10
PEG RatioValuation
1.994/10

Expensive relative to growth rate

Revenue GrowthGrowth
2.7%4/10

2.7% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Price/BookValuation
21.7x2/10

Trading at 21.7x book value

XXII4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.20M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-116.6%2/10

ROE of -116.6% — below average capital efficiency

Revenue GrowthGrowth
-43.1%2/10

Revenue declined 43.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : KMB

The strongest argument for KMB centers on Return on Equity.

Bull Case : XXII

The strongest argument for XXII centers on Price/Book.

Bear Case : KMB

The primary concerns for KMB are PEG Ratio, Revenue Growth, Piotroski F-Score. Debt-to-equity of 4.77 is elevated, increasing financial risk.

Bear Case : XXII

The primary concerns for XXII are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

KMB profiles as a value stock while XXII is a turnaround play — different risk/reward profiles.

XXII carries more volatility with a beta of 1.12 — expect wider price swings.

KMB is growing revenue faster at 2.7% — sustainability is the question.

KMB generates stronger free cash flow (575M), providing more financial flexibility.

Bottom Line

KMB scores higher overall (63/100 vs 31/100). XXII offers better value entry with a 70.6% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Kimberly-Clark Corporation

CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS · USA

Kimberly-Clark Corporation is an American multinational personal care corporation that produces mostly paper-based consumer products. The company manufactures sanitary paper products and surgical & medical instruments. Kimberly-Clark brand name products include Kleenex facial tissue, Kotex feminine hygiene products, Cottonelle, Scott and Andrex toilet paper, Wypall utility wipes, KimWipes scientific cleaning wipes and Huggies disposable diapers and baby wipes.

Visit Website →

22nd Century Group Inc

CONSUMER DEFENSIVE · TOBACCO · USA

22nd Century Group Inc (Ticker: XXII) is an innovative biopharmaceutical and agricultural company dedicated to tobacco harm reduction through advanced genetic engineering techniques. By focusing on the development of low-nicotine tobacco products, the firm aims to mitigate nicotine addiction while enhancing public health outcomes. As it strategically diversifies into the burgeoning hemp and cannabis markets, 22nd Century positions itself to capitalize on the expanding legal cannabis landscape. With a robust commitment to scientific research and adherence to regulatory frameworks, the company represents a compelling investment opportunity for institutional investors looking to engage in transformative sectors.

Want to dig deeper into these stocks?